Treatment Consistency Across Levels of Baseline Renal Warfarin

Circulation

135, 1001-1003

DOI: 10.1161/circulationaha.116.024666

Citation Report

#	Article	IF	Citations
1	Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. American Journal of Medicine, 2017, 130, 1015-1023.	3.2	43
2	The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. European Heart Journal, 2018, 39, 1330-1393.	14.7	1,815
3	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants. Mayo Clinic Proceedings, 2018, 93, 1503-1519.	3.7	14
4	Non–Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. Stroke, 2019, 50, 1480-1489.	9.1	23
5	Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. Stroke, 2019, 50, 1140-1148.	9.1	47
6	Consensus in Cardiology on Non-Vitamin-K Oral Anticoagulants for Patients With Atrial Fibrillation. Current Medical Research and Opinion, 2019, 35, 1571-1582.	2.9	1
7	The Impact of Renal Function on Efficacy and Safety of New Oral Anticoagulant in Atrial Fibrillation Patients: A Systemic Review and Meta-Analysis. Medicine (United States), 2019, 98, e18205.	2.1	9
8	Direct Oral Anticoagulants in Chronic Kidney Disease: An Update. Current Opinion in Nephrology and Hypertension, 2020, 29, 489.	3.1	31
9	Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel. CJC Open, 2020, 2, 641-651.	1.8	10
10	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs, 2020, 80, 1065-1083.	15.5	38
11	Impact of Creatinine Clearance on Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban: J-ELD AF Registry Subanalysis. American Heart Journal, 2020, 223, 23-33.	3.3	10
12	Cost-Effectiveness of Rivaroxaban Versus Warfarin in Non-Valvular Atrial Fibrillation Patients With Chronic Kidney Disease in China. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 658-668.	1.0	3
13	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. Journal of Clinical Pharmacology, 2021, 61, 1010-1026.	2.4	25
14	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience. Journal of Cardiovascular Pharmacology, 2020, 76, 671.	2.5	14
15	Применение ривароксабана для профилактики инсульта при неклапанной фибрилляции предсердий у больных пожилого и старческого возраста. Kardiologiya, 2019, 59, 4-11.	0.9	3
16	2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients With Atrial Fibrillation: How to Initiate and Organize the Follow-Up. Korean Journal of Medicine, 2019, 94, 17-39.	0.3	3
17	Risky Business: Judging the Use of Non-Vitamin K Antagonist Oral Anticoagulants for Non-Valvular Atrial Fibrillation in Patients With Renal Dysfunction. Journal of Atrial Fibrillation, 2018, 11, 2071.	0.1	2
18	New Aspects of Anticoagulant Therapy in Atrial Fibrillation in Patients With Renal Dysfunction. Russian Journal of Cardiology, 2020, 25, 4175.	1.9	2

#	Article	IF	Citations
19	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Advanced Chronic Kidney and Liver Diseases. European Heart Journal Supplements, 2022, 24, A11-A18.	2.9	4
20	Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention. Journal of Thrombosis and Haemostasis, 2022, 20, 1138-1145.	5.0	15
21	Levels and Dynamics of Estimated Glomerular Filtration Rate and Recurrent Vascular Events and Death in Patients With Minor Stroke or Transient Ischemic Attack. European Journal of Neurology, 2022, 29, 2716-2724.	4.4	3
22	Safety of Non-Vitamin K Antagonist Oral Anticoagulants: Concerns in Patients With Atrial Fibrillation and Glomerular Hyperfiltration?. European Heart Journal, 2023, 44, 322-325.	14.7	8
23	The Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With High-Normal Renal Function – A Systematic Review. Vascular Pharmacology, 2022, 147, 107123.	3.4	3
24	Impact of Increased Kidney Function on Clinical and Biological Outcomes in Real-World Patients Treated With Direct Oral Anticoagulants. PLoS ONE, 2022, 17, e0278693.	3.2	2
25	Pharmacokinetic Relevance of Glomerular Hyperfiltration for Drug Dosing. CKJ: Clinical Kidney Journal, 2023, 16, 1580-1586.	4.8	7
26	Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence. Current Problems in Cardiology, 2024, 49, 102017.	4.1	5
27	Prescription of DOACs in Patients With Atrial Fibrillation at Different Stages of Renal Insufficiency. Advances in Therapy, 2023, 40, 4264-4281.	5.0	20
28	Use of Direct Oral Anticoagulants for Venous Thromboembolism Treatment at Extremes of Body Weight, Renal and Liver Function: An Illustrated Review. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 102240.	3.3	7
29	Association of High-Estimated Glomerular Filtration Rate With the Severity of Ischemic Stroke During Non-Vitamin K Antagonist Oral Anticoagulants Therapy: A Nationwide Cohort Study. Frontiers in Neurology, 2023, 14, 1277855.	3.5	3
30	Selection of Non-Vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives From Vietnamese Experts. Part 2. European Cardiology Review, 2023, 18, e62.	2.4	8
31	Anticoagulation in Patients With Chronic Kidney Disease. American Journal of Nephrology, 2024, 55, 146-164.	3.9	54
32	Фибрилляция предсердий и полиморбидность: как выбрать идеальный прямой оральный антикоагулянт?. Meditsinskiy Sovet, 2024, 0, 54-62.	0.4	0
33	Risk of Bleeding, Thrombosis and Death Among Atrial Fibrillation Patients Treated With Oral Anticoagulants Across Estimated Glomerular Filtration Rates. American Journal of Cardiology, 2025, 238, 55-64.	2.4	1
34	Персонализированный подход к выбору антикоагулянтной терапии у пациентов с фибрилляцией предсердий в особых клинических случаях. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2024, 0, 178-183.	0.4	0
35	Efficacy and Safety of Direct Oral Anticoagulants for Patients With Atrial Fibrillation With Glomerular Hyperfiltration: A Systematic Review and Meta-Analysis. Clinical Therapeutics, 2025, 47, 798-806.	3.4	0
36	New Aspects of Anticoagulant Therapy in Atrial Fibrillation in Patients With Renal Dysfunction. Russian Journal of Cardiology, 2020, 25, 4175.	1.9	0

#	Article	IF	Citations
37	Conception et évaluation d'antidotes potentiels des anticoagulants oraux directs. , 0, .		0
38	Direct Oral Anticoagulants vs Warfarin in Asian vs Non-Asian Patients With Atrial Fibrillation: A Patient-Level Meta-Analysis From COMBINE AF. European Heart Journal, 2026, 47, 5172-5185.	14.7	6